Walk before you run: Feasibility challenges and lessons learned from the PROCLAIM study, a multicenter randomized controlled trial of misoprostol for prevention of recurrent C. difficile during COVID-19

Robert R. Lavieri, Erik R. Dubberke, Sarah K. McGill, Luther Bartelt, Stephanie A. Smith, Balint K. Pandur, Sharon E. Phillips, Krista Vermillion, Jana Shirey-Rice, Jill Pulley, Yaomin Xu, Christopher J. Lindsell, Nicole Zaleski, Rebecca Jerome, Ryan S. Doster, David M. Aronoff

Research output: Contribution to journalArticlepeer-review

1 Scopus citations

Abstract

We analyzed our challenging experience with a randomized controlled trial of misoprostol for prevention of recurrent C. difficile. Despite careful prescreening and thoughtful protocol modifications to facilitate enrollment, we closed the study early after enrolling just 7 participants over 3 years. We share lessons learned, noting the importance of feasibility studies, inclusion of biomarker outcomes, and dissemination of such findings to inform future research design and implementation successes.

Original languageEnglish
Article number102699
JournalAnaerobe
Volume80
DOIs
StatePublished - Apr 2023

Keywords

  • BioVU
  • C. difficile
  • Clostridioides difficile
  • Misoprostol
  • PheWAS
  • Trial design

Fingerprint

Dive into the research topics of 'Walk before you run: Feasibility challenges and lessons learned from the PROCLAIM study, a multicenter randomized controlled trial of misoprostol for prevention of recurrent C. difficile during COVID-19'. Together they form a unique fingerprint.

Cite this